Enrollment completed for Ph 2b study of BO-112 in basal cell carcinoma population
Mercedes Diz, CEO of Highlight Therapeutics, said: “The completion of enrollment in SPOTLIGHT-204 represents an important step in our strategy to develop innovative and scalable dermato-oncology therapies. BCC is a high-incidence disease in which treatment paradigms have remained largely unchanged for decades, particularly for patients with lesions in cosmetically and functionally sensitive areas. By advancing BO-112 in this Phase IIb study, we aim to help redefine the role of intratumoral immunotherapy in BCC.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.